Since our founding in 2020, Resilience has focused on improving the pharmaceutical supply chain and providing manufacturers of complex, advanced medicines the ability to produce drugs at scale and on ...

CINCINNATI--(BUSINESS WIRE)--National Resilience (“Resilience”), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced long-term debt ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

Revenues for the year ended December 31, 2025, were $1.3 million, compared to $0.7 million for the year ended December 31, 2024. The increase reflects continued expansion of Scinai's CDMO activities.

Altitude Marketing released its 2026 CDMO Marketing Trends Report, a quantitative analysis of marketing practices and organizational dynamics across the U.S. contract development and manufacturing ...

Samsung Biologics is accelerating its global biopharmaceutical market strategy by rebranding as a ‘pure CDMO (Contract Development and Manufacturing Organization)’ entity. The company has clarified ...

The acquisition will establish Zydus' presence in fast growing global biologics CDMO space. Acquired capabilities include cutting-edge biologics development and manufacturing services to serve the ...

New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations This financing underscores Resilience’s critical role as a CDMO manufacturing sterile drugs at scale and ...